¼¼°èÀÇ ¼ÒÈ­±â Áø´Ü ½ÃÀå
Gastrointestinal Diagnostics
»óǰÄÚµå : 1774871
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 478 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¼ÒÈ­±â Áø´Ü ½ÃÀåÀº 2030³â±îÁö 58¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 49¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼ÒÈ­±â Áø´Ü ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 2.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 58¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ³»½Ã°æ°Ë»ç´Â CAGR 2.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 16¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ç÷¾×°Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£À» ÅëÇØ¼­ CAGR 1.9%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 13¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¼ÒÈ­±â Áø´Ü ½ÃÀåÀº 2024³â¿¡ 13¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.1%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.1%¿Í 2.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ¼ÒÈ­±â Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼ÒÈ­±â Áø´ÜǰÀÇ ¹ßÀüÀ¸·Î ÀÎÇÑ Áúº´ ¹ß°ßÀÇ °³¼±Àº?

¼ÒÈ­±â(GI) ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Á¶±â ¹× Á¤È®ÇÑ Áúȯ Áø´ÜÀÇ Çʿ伺À¸·Î ÀÎÇØ ÃÖ±Ù ¸î ³â µ¿¾È ¼ÒÈ­±â(GI) Áø´Ü ±â¼úÀÌ Å©°Ô ¹ßÀüÇØ ¿Ô½À´Ï´Ù. ¿°Áõ¼º ÀåÁúȯ(IBD), ´ëÀå¾Ï, ¼ÒÈ­¼º ±Ë¾ç, À§½Äµµ ¿ª·ùÁúȯ(GERD), ü°­³»½Ã°æ, ´ëÀå¾Ï, À§½Äµµ ¿ª·ùÁúȯ, ü°­³»½Ã°æ, ´ëÀå³»½Ã°æ, ³»½Ã°æ, ´ëÀå¾Ï, À§½Äµµ ¿ª·ùÁúȯ µîÀÇ Ä¡·á´Â È¿°úÀûÀÎ Ä¡·á¸¦ º¸ÀåÇϱâ À§ÇØ Àû½Ã¿¡ Á¤È®ÇÑ Áø´Ü µµ±¸°¡ ÇÊ¿äÇÕ´Ï´Ù. ³»½Ã°æ °Ë»ç, ´ëÀå ³»½Ã°æ °Ë»ç, ´ëº¯ °Ë»ç¿Í °°Àº ÀüÅëÀûÀÎ Áø´Ü¹ýÀº ¿©ÀüÈ÷ ¼ÒÈ­±â Áúȯ ¹ß°ßÀÇ ÇÙ½ÉÀÌÁö¸¸, »õ·Î¿î ±â¼úÀ» ÅëÇØ Áø´Ü Á¤È®µµ°¡ Çâ»óµÇ°í °Ë»ç ½Ã°£ÀÌ ´ÜÃàµÇ¾î ȯÀÚÀÇ ¿¹Èİ¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

ÃÖ±Ù ¼ÒÈ­°ü Áø´ÜÀÇ ±â¼ú Çõ½Å¿¡´Â ĸ½¶ ³»½Ã°æ °Ë»ç, ºÐÀÚ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç, ÀΰøÁö´É(AI) Áö¿ø ¿µ»ó Áø´Ü µîÀÌ ÀÖ½À´Ï´Ù. ĸ½¶ ³»½Ã°æ °Ë»ç´Â ±âÁ¸ ³»½Ã°æ °Ë»ç·Î´Â Æò°¡Çϱ⠾î·Á¿î ¼ÒÈ­°ü Àüü, ƯÈ÷ ¼ÒÀåÀ» ºñħ½ÀÀûÀ¸·Î ½Ã°¢È­ÇÒ ¼ö ÀÖÀ¸¸ç, AI ±â¹Ý Áø´Ü µµ±¸´Â ³»½Ã°æ ¿µ»ó¿¡¼­ Àü¾Ï º´º¯, ¿ëÁ¾ ¹× ±âŸ ÀÌ»ó ¡Èĸ¦ °³¼±Çϰí ÀÎÀû ¿À·ùÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ, ¾×ü»ý°Ë°ú ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ºÐ¼®ÀÇ ¹ßÀüÀ¸·Î °³ÀÎ ¸ÂÃãÇü Áø´ÜÀÌ °¡´ÉÇØÁ® Àǻ簡 °³º° ȯÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á Àü·«À» Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó ¼ÒÈ­±â Áø´ÜÀº ´õ¿í Á¢±ÙÇϱ⠽±°í, È¿À²ÀûÀ̸ç, Á¤È®µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀ» ÁÖµµÇÏ´Â GI Áø´Ü ±â¼úÀº?

º´¿ø, Áø´Ü ½ÇÇè½Ç, ¿Ü·¡Áø·á¼¾ÅÍ µî ´Ù¾çÇÑ ÇコÄɾî ȯ°æ¿¡¼­ ÷´Ü ¼ÒÈ­±â Áø´Ü Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³»½Ã°æ °Ë»ç´Â ¿©ÀüÈ÷ ¼ÒÈ­±â Áúȯ Áø´ÜÀÇ Ç¥ÁØÀÌÁö¸¸, °øÃÊÁ¡ ·¹ÀÌÀú ³»½Ã°æ(CLE) ¹× Çü±¤ ³»½Ã°æ°ú °°Àº »õ·Î¿î ¿µ»ó Áø´Ü¹ýÀÌ Á¡¸·ÀÇ ÀÌ»óÀ» ½Ç½Ã°£À¸·Î °¨ÁöÇÏ´Â ´É·ÂÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ½Äµµ ¿îµ¿Àå¾Ö Áø´ÜÀ» À§ÇØ °íÇØ»óµµ ¸¸³ë¸ÞÆ®¸®(HRM)µµ ½Äµµ ¿îµ¿Àå¾Ö Áø´Ü¿¡ Ȱ¿ëµÇ°í ÀÖÀ¸¸ç, »ïÅ´ ±â´É Àå¾Ö ¹× ¿ª·ù °ü·Ã Áúȯ¿¡ ´ëÇÑ ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

ºÐÀÚÁø´ÜÇÐ ¹× À¯ÀüÀÚ °Ë»ç´Â ¼ÒÈ­±â¾Ï ¹× À¯Àü¼º ¼ÒÈ­±â ÁúȯÀÇ Á¶±â ¹ß°ß¿¡ À־µµ Á¡Á¡ ´õ Å« ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)À» ÅëÇØ ¸°Ä¡ ÁõÈıºÀ̳ª À¯Àü¼º ÃéÀå¿°°ú °°Àº Áúȯ°ú °ü·ÃµÈ À¯ÀüÀÚ º¯À̸¦ Á¤È®ÇÏ°Ô ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾î ¿¹¹æÀû Áúº´ °ü¸®°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®±Õ, Ŭ·Î½ºÆ®¸®µã µðÇǽDZհú °°Àº ¼ÒÈ­±â °¨¿°¿¡ ´ëÇÑ ÇöÀåÁø´Ü°Ë»ç(POCT)ÀÇ µîÀåÀ¸·Î ½Å¼ÓÇÑ Áø´Ü°ú Ä¡·á ½ÃÀÛÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ºñħ½ÀÀû, Àúħ½ÀÀû Áø´Ü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ÒÈ­±â Áø´Ü ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼ÒÈ­±â Áø´Ü¾àÀÇ Ãֽбâ¼ú ¹ßÀüÀº ¹«¾ùÀΰ¡?

±â¼ú Çõ½ÅÀº °¨Áö ´É·Â °­È­, ½Ã¼ú ½Ã°£ ´ÜÃà, ȯÀÚ ÆíÀǼº Çâ»óÀ¸·Î ¼ÒÈ­±â Áø´Ü ÀǾàǰÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ Çõ½Å Áß Çϳª´Â ³»½Ã°æ°ú ¿µ»ó 󸮿¡ AI¸¦ ÅëÇÕÇÑ °ÍÀ¸·Î, AI ¾Ë°í¸®ÁòÀº ³»½Ã°æ ¿µ»óÀ» ½Ç½Ã°£À¸·Î ºÐ¼®ÇÏ¿© ¿ëÁ¾, Á¾¾ç, ¿°Áõ°ú °°Àº ÀÌ»ó ¡Èĸ¦ Á¤È®ÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ³»½Ã°æ Àǻ簡 Á¶±â ´ëÀå¾Ï ¹× Àü¾Ï º´º¯À» º¸´Ù È¿°úÀûÀ¸·Î ¹ß°ßÇϰí Áø´Ü ´©¶ô·üÀ» ³·Ãß´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¶ÇÇÑ, ¾×ü »ý°ËÀº ºñħ½ÀÀûÀÎ ¼ÒÈ­±â¾Ï °Ë»çÀÇ È¹±âÀûÀÎ µµ±¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¾×ü »ý°ËÀº Ç÷¾× ³» ¼øÈ¯ Á¾¾ç DNA(ctDNA) ¹× ±âŸ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ºÐ¼®ÇÔÀ¸·Î½á ±âÁ¸ÀÇ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â ÃÖ¼Ò Ä§½ÀÀû °Ë»ç ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¿ä ¹ßÀüÀº ½º¸¶Æ® ĸ½¶ ³»½Ã°æÀÇ °³¹ßÀÔ´Ï´Ù. ½º¸¶Æ® ĸ½¶ ³»½Ã°æÀº ÀåÀÇ ¿îµ¿¼º°ú pH °ªÀ» ¹«¼±À¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ¾î ÁøÁ¤Á¦³ª º´¿ø ¹æ¹® ¾øÀ̵µ ¼ÒÈ­±â °Ç°­¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀº ¼ÒÈ­±â Áø´ÜÀ» º¸´Ù È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀ¸·Î ¸¸µé¾î Áúº´À» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¼ÒÈ­±â Áø´Ü¾à ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼ÒÈ­±â Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº ¼ÒÈ­±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÷´Ü ¿µ»ó ±â¼úÀÇ Ã¤Åà Áõ°¡, ºñħ½ÀÀû Áø´Ü ¹æ¹ýÀ¸·ÎÀÇ Àüȯ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´ëÀå¾Ï°ú ¿°Áõ¼º Àå ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â °ËÁø ¹× Á¤¹Ð Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ëÀå¾Ï °ËÁø ÇÁ·Î±×·¥À» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

AI Áö¿ø ³»½Ã°æ, ¾×ü »ý°Ë, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ±â¹Ý Áø´Ü µîÀÇ ±â¼ú ¹ßÀüÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÇ·á Á¢±Ù¼ºÀÌ ³·Àº Áö¿ªÀÇ È¯ÀÚµéÀÇ ¼ÒÈ­±â Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀçÅà ¹× ÇöÀå °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ Çコ Ç÷§ÆûÀÇ È®´ë·Î ÀÎÇØ ¿ø°ÝÁö¿¡¼­µµ GI °Ë»ç ¹× Áø´Ü Æò°¡°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀÌ Á¶±â ¹ß°ß°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Á߿伺À» °è¼Ó °­Á¶Çϰí ÀÖ´Â °¡¿îµ¥, ¼ÒÈ­±â Áø´Ü ½ÃÀåÀº ±â¼ú Çõ½Å°ú ÀÇ·á ÀÎ½Ä Áõ°¡¿¡ ÈûÀÔ¾î Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

°Ë»ç(³»½Ã°æ °Ë»ç, Ç÷¾× °Ë»ç, ÇǷθ®±Õ °Ë»ç, Ä«¸£ÇÁ·ÎÅ×ũƾ °Ë»ç, ¸é¿ª±Û·ÎºÒ¸° °Ë»ç, ±âŸ ¼ÒÈ­±â Áø´Ü °Ë»ç), ±â¼ú(ELISA ±â¼ú, PCR ±â¼ú, ¹Ì»ý¹°ÇÐ ±â¼ú, ±âŸ ±â¼ú), °Ë»ç Àå¼Ò(Áß¾Ó °Ë»ç½Ç, POC(Point of Care) °Ë»ç½Ç), ¿ëµµ(°¨¿°Áõ, ¿°Áõ¼ºÀå Áúȯ ¿ëµµ, À§½Äµµ ¿ª·ùÁõ ¿ëµµ, ¾Ï ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gastrointestinal Diagnostics Market to Reach US$5.8 Billion by 2030

The global market for Gastrointestinal Diagnostics estimated at US$4.9 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2024-2030. Endoscopy Test, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Blood Test segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.1% CAGR

The Gastrointestinal Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Gastrointestinal Diagnostics Market - Key Trends & Drivers Summarized

How Are Advancements in Gastrointestinal Diagnostics Improving Disease Detection?

Gastrointestinal (GI) diagnostics have witnessed significant advancements in recent years, driven by the increasing prevalence of GI disorders and the need for early and accurate disease detection. Conditions such as inflammatory bowel disease (IBD), colorectal cancer, peptic ulcers, gastroesophageal reflux disease (GERD), and celiac disease require timely and precise diagnostic tools to ensure effective treatment. Traditional diagnostic methods such as endoscopy, colonoscopy, and stool analysis remain the cornerstone of GI disease detection, but emerging technologies are enhancing diagnostic accuracy, reducing procedure times, and improving patient outcomes.

Recent innovations in GI diagnostics include capsule endoscopy, molecular biomarker testing, and artificial intelligence (AI)-assisted imaging. Capsule endoscopy enables non-invasive visualization of the entire digestive tract, particularly the small intestine, which is difficult to assess using conventional endoscopy. AI-powered diagnostic tools are improving the detection of precancerous lesions, polyps, and other abnormalities in endoscopic images, reducing the risk of human error. Furthermore, advancements in liquid biopsy and microbiome analysis are enabling personalized diagnostics, helping physicians tailor treatment strategies based on individual patient profiles. As these technologies continue to evolve, gastrointestinal diagnostics are becoming more accessible, efficient, and precise.

Which GI Diagnostic Technologies Are Driving Market Growth?

The demand for advanced gastrointestinal diagnostics is growing across multiple healthcare settings, including hospitals, diagnostic laboratories, and ambulatory care centers. Endoscopy remains the gold standard for diagnosing GI disorders, but new imaging modalities such as confocal laser endomicroscopy (CLE) and fluorescence endoscopy are enhancing the ability to detect mucosal abnormalities in real time. High-resolution manometry (HRM) is also being increasingly adopted for diagnosing esophageal motility disorders, providing valuable insights into swallowing dysfunction and reflux-related conditions.

Molecular diagnostics and genetic testing are also playing a growing role in the early detection of gastrointestinal cancers and hereditary GI diseases. Next-generation sequencing (NGS) enables precise identification of genetic mutations linked to conditions such as Lynch syndrome and hereditary pancreatitis, allowing for proactive disease management. Additionally, the rise of point-of-care testing (POCT) for GI infections, such as Helicobacter pylori and Clostridium difficile, has improved rapid diagnosis and treatment initiation. With the increasing focus on non-invasive and minimally invasive diagnostics, the GI diagnostics market is poised for substantial expansion in the coming years.

What Are the Latest Technological Advancements in Gastrointestinal Diagnostics?

Technological innovations are transforming gastrointestinal diagnostics by enhancing detection capabilities, reducing procedure times, and improving patient comfort. One of the most significant breakthroughs is the integration of AI into endoscopic and imaging procedures. AI algorithms can analyze endoscopic videos in real time, identifying abnormalities such as polyps, tumors, and inflammation with high accuracy. This technology is helping endoscopists detect early-stage colorectal cancer and precancerous lesions more effectively, reducing the incidence of missed diagnoses.

Additionally, liquid biopsy is emerging as a revolutionary tool for non-invasive GI cancer detection. By analyzing circulating tumor DNA (ctDNA) and other biomarkers in the blood, liquid biopsy offers a less invasive alternative to traditional biopsy procedures. Another key advancement is the development of smart capsule endoscopy, which enables wireless monitoring of gut motility and pH levels, providing valuable insights into digestive health without requiring sedation or hospital visits. These innovations are making GI diagnostics more efficient, patient-friendly, and capable of detecting diseases at earlier stages.

What Factors Are Fueling the Growth of the Gastrointestinal Diagnostics Market?

The growth in the gastrointestinal diagnostics market is driven by several factors, including the rising incidence of GI disorders, increasing adoption of advanced imaging technologies, and the shift toward non-invasive diagnostic methods. The global burden of colorectal cancer and inflammatory bowel diseases has led to greater demand for early screening and precision diagnostics. Government initiatives promoting colon cancer screening programs and improved healthcare infrastructure have also contributed to market expansion.

Technological advancements, such as AI-assisted endoscopy, liquid biopsy, and microbiome-based diagnostics, are further accelerating market growth. The increasing preference for home-based and point-of-care testing solutions has expanded patient access to GI diagnostics, particularly in underserved regions. Additionally, the expansion of telemedicine and digital health platforms is enabling remote GI consultations and diagnostic assessments. As healthcare providers continue to emphasize early detection and personalized medicine, the gastrointestinal diagnostics market is expected to experience sustained growth, driven by innovation and rising healthcare awareness.

SCOPE OF STUDY:

The report analyzes the Gastrointestinal Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test (Endoscopy Test, Blood Test, H. Pylori Test, Calprotectin Test, Immunoglobulin Test, Other Gastrointestinal Diagnostics Tests); Technology (ELISA Technology, PCR Technology, Microbiology Technology, Other Technologies); Test Location (Central Laboratories Test Location, Point-of-Care Test Location); Application (Infection, Inflammatory Bowel Disease Application, Gastroesophageal Reflux Disease Application, Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â